Prompted in part by the COVID-19 pandemic, the T.H. Chan School of Public Health at Harvard University

African genomics research company 54gene said on Tuesday that it has closed a $15 million Series A financing round.

A multi-omic analysis of high-grade serous ovarian cancer has uncovered molecular differences between clinical subgroups of the disease.

The US Food and Drug Administration on Monday granted Emergency Use Authorization to two lab-developed real-time RT-PCR tests for SARS-CoV-2, the virus that causes coronavirus disease COVID-19.

Illumina reported after the close of the market on Tuesday preliminary first quarter revenues of approximately $858 million. The firm also withdrew its full-year revenue guidance due to disruption from the COVID-19 pandemic.

Fluidigm said after the close of the market on Tuesday that it expects Q1 revenues of approximately $27.6 million.

A new research portal from software developer Nference and Johnson & Johnson's Janssen Pharmaceutica has identified several new expression mechanisms for COVID-19 and the novel SARS-CoV-2 coronavirus that causes the deadly disease.

The National Institutes of Health have started recruiting for a new study that aims to determine how many adults in the US who have not had a confirmed infection with SARS-CoV-2 carry antibodies to the virus, indicating that they were previously infected.

From a purple dot in Wuhan, China, lines start to emerge, reaching the UK, Thailand, and Australia.

LexaGene, which has developed a pathogen detection platform for the veterinary and food safety sectors, is now pivoting to clinical diagnostics by modifying its LX Analyzer platform for viruses

A team led by researchers at St. Jude Children's Research Hospital, the European Molecular Biology Laboratory

Dr. Nefertiti Brown, who is an attending physician in California, was tested for COVID-19 on March 18th after displaying symptoms of the virus.

The new five-minute test is the second Abbott test to receive emergency use authorization by FDA for COVID-19 detection. Combined, Abbott expects to produce about 5 million tests a month.

A U.S. government contract is expected to accelerate the development, validation, and FDA clearance of Cue Health's portable, molecular diagnostic test to detect SARS-CoV-2

Grail had a huge win in the liquid biopsy space this week. The Menlo Park, CA-based company said results of its Circulating Cell-Free Genome Atlas study show its technology can detect 50 cancer types across all stages with a very low false-positive rate.